Jocavio
Fukuoka, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Japanese biotech developing next-generation vaccinia virus-based oncolytic immunotherapies to eradicate cancer.
Oncology
Technology Platform
Genetic engineering platform for vaccinia virus to create next-generation oncolytic virotherapies designed to lyse tumor cells and induce robust, long-term anti-tumor immunity.
Opportunities
The growing oncology immunotherapy market and demand for improved oncolytic viruses with stronger systemic immune activation present a significant opportunity for their next-generation platform.
Risk Factors
High preclinical and clinical development risk inherent to novel biologics, intense competition in the cancer immunotherapy space, and reliance on future funding to achieve clinical milestones.
Competitive Landscape
Competes with other oncolytic virus developers like Amgen (T-VEC), Replimune, and Turnstone Biologics. Aims to differentiate through vaccinia virus engineering for enhanced and sustained anti-tumor immune response.